Latest Administration News

Insignia Financial’s Funds Under Management and Administration edged up to $342 billion, driven by strong inflows into its Wrap platform and multi-asset solutions, while Master Trust funds faced ongoing outflows amid product transitions.

Netwealth Group Limited reported a strong December quarter with record custodial inflows of $8.4 billion and total funds under administration reaching $125.6 billion, while announcing a $101 million compensation charge related to the First Guardian collapse.

Pro-Pac Packaging Group’s Australian and New Zealand operations have been sold to Knoxcorp subsidiaries, while the Perfection Packaging unit is set to shut down by February 2026.

Praemium Limited reported a 14% year-on-year increase in total Funds Under Administration to $70.5 billion for Q2 FY26, completing the OneVue transition and seeing strong net inflows in its Spectrum and Powerwrap platforms.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

HUB24 has reported record net inflows of $5.6 billion in Q2 FY26, pushing total funds under administration to $152.3 billion and expanding its market share to 9.3%. The company also unveiled a new lifetime retirement solution and an AI-driven adviser ecosystem.

Vinyl Group Ltd has reported a landmark quarter with record cash receipts up 80% quarter-on-quarter and its first operating cash flow positive result, signalling a turning point for the music and culture company.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.

Pacific Edge reports a 13.4% decline in test volumes for Q3 2026 but gains strategic momentum with a key Medicare advisory meeting and clinical endorsements poised to influence reimbursement policy.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.